Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10836094 | 0.92 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PKML3MBTL1 | |
| SCHEMBL18289526 | 0.89 | CYP19A1 (0.50) | L3MBTL1CA1CA2CA9BCHE | |
| SCHEMBL6654974 | 0.88 | LMNA (0.56) | CHRM2CHRM1CHRM3TAAR1LMNA | |
| SCHEMBL31618046 | 0.87 | HTT (0.51) | L3MBTL1 | |
| SCHEMBL6963150 | 0.87 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PKML3MBTL1 | |
| SCHEMBL8993165 | 0.86 | PKM (0.52) | CHRM2CHRM1CHRM3PKML3MBTL1 | |
| SCHEMBL6803332 | 0.83 | ALDH1A1 (0.55) | LMNABCHEACHE | |
| SCHEMBL9842931 | 0.83 | CA12 (0.56) | LMNACA1CA2CA9 | |
| SCHEMBL6001846 | 0.83 | MGLL (0.46) | CA1CA2CA7CA9 | |
| SCHEMBL8098024 | 0.82 | EGFR (0.51) | TAAR1CA1CA9MAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20060089340-A1 | Novel steroids and steroid mimetics; method for their production; and use thereof | STERIX LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314733-A1 | Indole-2-carboxamides as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| US-20020132802-A1 | Cytoprotective polycyclic compounds | WASHINGTON UNIVERISTY | 2002-09-19 | — | — | US | disclosed |
| WO-2002040032-A2 | CYTOPROTECTIVE ESTROGEN DERIVATIVES | WASHINGTON UNIVERSITY (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | CHRM2 40/4885CHRM1 43/4885CHRM3 262/4885 |
| US-20060089340-A1 | Novel steroids and steroid mimetics; method for their production; and use thereof | CYP17A1, CYP21A2, HSD17B1 | CHRM2 4389/4885CHRM1 3871/4885CHRM3 3776/4885 |
| US-20020132802-A1 | Cytoprotective polycyclic compounds | NFE2L2, TXNRD2, ESR2 | CHRM2 3351/4885CHRM1 3081/4885CHRM3 3101/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | CHRM2 161/4885CHRM1 149/4885CHRM3 933/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | CHRM2 41/4885CHRM1 44/4885CHRM3 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.